Status:
TERMINATED
Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
BMS-275183 given orally twice weekly to patients pretreated for locally advanced or metastatic NSCLC will show anti-tumor activity in any of the 3 separate cohorts of the patients enrolled: * Cohort ...
Eligibility Criteria
Inclusion
- Men and women, age \>= 18 years
- Subjects with histologically or cytologically confirmed locally advanced or metastatic NSCLC who failed only one prior chemotherapy regimen.
Exclusion
- Concomitant medication with a cytochrome P450 (CYP) 3A4 inhibitor or inducer
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
186 Patients enrolled
Trial Details
Trial ID
NCT00359450
Start Date
July 1 2006
Last Update
March 2 2010
Active Locations (30)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Burlington, Massachusetts, United States
2
Local Institution
St Louis, Missouri, United States
3
Local Institution
Morganton, North Carolina, United States
4
Local Institution
Cleveland, Ohio, United States